Lv3
330 积分 2022-05-17 加入
High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRASG12C by Intact Protein MS and Targeted MRM
1个月前
已完结
Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity
1个月前
已完结
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
2个月前
已完结
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy
2个月前
已完结
PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies
3个月前
已完结
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer
3个月前
已完结
All Roads Lead to Rome: YAP/TAZ Activity Influences Efficacy of KRASG12C Inhibitors
3个月前
已完结
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
3个月前
已完结
Targeting TEAD-ious resistance
3个月前
已完结
Development of RMC-6236, a potent and orally bioavailable RAS(ON) multi-selective tri-complex inhibitor for the treatment of RAS-addicted cancers by targeting multiple RAS variants
3个月前
已完结
皖公网安备34019202002308
